Literature DB >> 26380599

Treating with Checkpoint Inhibitors-Figure $1 Million per Patient.

Audrey Andrews.   

Abstract

Entities:  

Year:  2015        PMID： 26380599      PMCID： PMC4570079     

Source DB:  PubMed          Journal:  Am Health Drug Benefits        ISSN： 1942-2962


× No keyword cloud information.
  43 in total

Review 1.  Cancer drug development: The missing links.

Authors:  Ajaikumar B Kunnumakkara; Devivasha Bordoloi; Bethsebie Lalduhsaki Sailo; Nand Kishor Roy; Krishan Kumar Thakur; Kishore Banik; Mehdi Shakibaei; Subash C Gupta; Bharat B Aggarwal
Journal:  Exp Biol Med (Maywood)       Date:  2019-04-08

Review 2.  Immunotherapy of Melanoma: Facts and Hopes.

Authors:  Sarah A Weiss; Jedd D Wolchok; Mario Sznol
Journal:  Clin Cancer Res       Date:  2019-03-28       Impact factor: 12.531

3.  The sphingosine kinase 2 inhibitor ABC294640 displays anti-non-small cell lung cancer activities in vitro and in vivo.

Authors:  Lu Dai; Charles D Smith; Maryam Foroozesh; Lucio Miele; Zhiqiang Qin
Journal:  Int J Cancer       Date:  2018-01-04       Impact factor: 7.396

Review 4.  T cell costimulation, checkpoint inhibitors and anti-tumor therapy.

Authors:  Dipankar Nandi; Sanmoy Pathak; Taru Verma; Madhulika Singh; Avik Chattopadhyay; Samriddhi Thakur; Abinaya Raghavan; Abhijeet Gokhroo
Journal:  J Biosci       Date:  2020       Impact factor: 1.826

5.  DNA-Based Delivery of Checkpoint Inhibitors in Muscle and Tumor Enables Long-Term Responses with Distinct Exposure.

Authors:  Liesl Jacobs; Elien De Smidt; Nick Geukens; Paul Declerck; Kevin Hollevoet
Journal:  Mol Ther       Date:  2020-02-13       Impact factor: 11.454

Review 6.  Evaluating tumor response with FDG PET: updates on PERCIST, comparison with EORTC criteria and clues to future developments.

Authors:  Katja Pinker; Christopher Riedl; Wolfgang A Weber
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-03-30       Impact factor: 9.236

7.  Evaluating for Pseudoprogression in Colorectal and Pancreatic Tumors Treated With Immunotherapy.

Authors:  Christine M Parseghian; Madhavi Patnana; Priya Bhosale; Kenneth R Hess; Ya-Chen Tina Shih; Bumyang Kim; Scott Kopetz; Michael J Overman; Gauri R Varadhachary; Milind Javle; Aung Naing; Sarina Piha-Paul; David Hong; Hung Le; Vivek Subbiah; Shubham Pant
Journal:  J Immunother       Date:  2018 Jul/Aug       Impact factor: 4.456

8.  Myocarditis in Patients Treated With Immune Checkpoint Inhibitors.

Authors:  Syed S Mahmood; Michael G Fradley; Justine V Cohen; Anju Nohria; Kerry L Reynolds; Lucie M Heinzerling; Ryan J Sullivan; Rongras Damrongwatanasuk; Carol L Chen; Dipti Gupta; Michael C Kirchberger; Magid Awadalla; Malek Z O Hassan; Javid J Moslehi; Sachin P Shah; Sarju Ganatra; Paaladinesh Thavendiranathan; Donald P Lawrence; John D Groarke; Tomas G Neilan
Journal:  J Am Coll Cardiol       Date:  2018-03-19       Impact factor: 24.094

9.  From the Guest Editors: Recent Advances and Evolving Challenges in Treating Unresectable Melanoma.

Authors:  Sarah A Weiss; Harriet M Kluger
Journal:  Cancer J       Date:  2017 Jan/Feb       Impact factor: 3.360

10.  Synthetic DNA-Encoded Monoclonal Antibody Delivery of Anti-CTLA-4 Antibodies Induces Tumor Shrinkage In Vivo.

Authors:  Elizabeth K Duperret; Aspen Trautz; Regina Stoltz; Ami Patel; Megan C Wise; Alfredo Perales-Puchalt; Trevor Smith; Kate E Broderick; Emma Masteller; J Joseph Kim; Laurent Humeau; Kar Muthumani; David B Weiner
Journal:  Cancer Res       Date:  2018-10-04       Impact factor: 12.701
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.